AZN

AstraZeneca (AZN)

AstraZeneca PLC

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:AZN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/23	20:00	Business Wire	Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/09/23	19:44	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/09/23	19:32	IH Market News	Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More	NASDAQ:AZN	AstraZeneca PLC
2024/09/23	19:27	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/09/21	05:34	Business Wire	FLUMIST approved for self-administration in the US	NASDAQ:AZN	AstraZeneca PLC
2024/09/18	20:00	Business Wire	FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis	NASDAQ:AZN	AstraZeneca PLC
2024/09/18	00:22	GlobeNewswire Inc.	International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024	NASDAQ:AZN	AstraZeneca PLC
2024/09/16	20:00	Business Wire	IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/09/15	23:30	Business Wire	IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/09/13	23:00	Business Wire	ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases	NASDAQ:AZN	AstraZeneca PLC
2024/09/10	23:28	PR Newswire (US)	SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing	NASDAQ:AZN	AstraZeneca PLC
2024/09/10	23:16	PR Newswire (US)	SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing	NASDAQ:AZN	AstraZeneca PLC
2024/09/10	19:02	IH Market News	Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9%	NASDAQ:AZN	AstraZeneca PLC
2024/09/10	02:50	Business Wire	Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/09/09	01:25	Business Wire	Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/09/05	19:11	IH Market News	Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing	NASDAQ:AZN	AstraZeneca PLC
2024/09/03	20:00	Business Wire	AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024	NASDAQ:AZN	AstraZeneca PLC
2024/08/23	21:20	IH Market News	Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1%	NASDAQ:AZN	AstraZeneca PLC
2024/08/16	20:00	Business Wire	IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery	NASDAQ:AZN	AstraZeneca PLC
2024/08/16	19:21	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/08/15	20:00	Business Wire	IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US	NASDAQ:AZN	AstraZeneca PLC
2024/07/30	19:26	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/07/30	19:00	IH Market News	Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots	NASDAQ:AZN	AstraZeneca PLC
2024/07/29	20:00	Business Wire	Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/07/29	19:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/07/25	20:00	Business Wire	AstraZeneca’s H1 and Q2 2024 Financial Results	NASDAQ:AZN	AstraZeneca PLC
2024/07/25	19:21	IH Market News	U.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire Expectations	NASDAQ:AZN	AstraZeneca PLC
2024/07/25	19:19	IH Market News	Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5%	NASDAQ:AZN	AstraZeneca PLC
2024/07/23	20:00	PR Newswire (Canada)	Voydeya est approuvé au Canada à titre de traitement d'appoint au ravulizumab ou à l'éculizumab chez les adultes atteints d'une maladie rare, appelée HPN, qui présentent une anémie hémolytique résiduelle attribuable à une hémolyse extravasculair	NASDAQ:AZN	AstraZeneca PLC
2024/07/23	20:00	PR Newswire (Canada)	Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysis	NASDAQ:AZN	AstraZeneca PLC